Dasatinib is a novel tyrosine kinase inhibitor (TKI) of BCR-ABL and SRC family kinases that has shown promising therapeutic effects in patients with chronic myeloid leukemia (CML) [1–6]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.